ABSTRACT

Background In our previous standard controlled clinical study, a polyherbal Unani drug consisting of Colchicum luteum, Aloe barbadensis, Carthamus tinctorious, Terminalia chebula and Zanjabeel Zingiber officinalis in their crude forms, was tested in patients of acute gouty arthritis and found better than the standard drug allopurinol in terms of efficacy as well as safety, when administered in a dose of 6 gm per day to the patients with gout. Objectives To reduce the dosing load, 50% hydroalcoholic extract of this polyherbal Unani drug was tested and compared with its initial crude form for its efficacy and safety in patients of hyperuricemia with acute gouty arthritis. Methods A total of 40 patients aged between 18-65 years with clinical signs and symptoms of gouty arthritis with a serum uric acid more than 7 mg/dL were randomized into test and control groups to receive either hydroalcoholic extract (600 mg daily in 2 divided doses) or crude form of the polyherbal drug (6 gm daily in 3 divided doses). respectively for 6 weeks. Results Both hydroalcoholic extract and crude forms of Polyherbal formulation at a dose of 600 mg and 6 gm respectively (1:10) produced remarkable effects on various efficacy parameters in gouty arthritis and also reduced serum uric acid level below 6 mg/dL. The test formulation (hydroalcoholic extract) was well tolerated and no adverse/ side effects were observed during the entire period of protocol therapy in any patient in the test group, unlike control drug (crude form) which produced diarrhoea and abdominal cramps in 25% of patients. Conclusion Hydroalcoholic extract of polyherbal Unani drug was found better tolerated than its crude form, and the dosing load was also reduced to one-tenth of its crude form. Keywords: Gout, Arthritis, hyperuricemia, Polyherbal, Colchicum luteum
Publication date: 01/12/2022

https://ijbpas.com/pdf/2022/December/MS_IJBPAS_2022_6663.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.12.6663